Everything below concerns Albumin conjugation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-14. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
In February 2020, bempedoic acid was approved for use in the United States both as a standalone drug (brand name Nexletol) and in a fixed-dose combination with ezetimibe (brand name Nexlizet). The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. The FDA approved bempedoic acid based on evidence from two clinical trials (Trial 1/ NCT02666664 and Trial 2/NCT02991118) of 3009 subjects with high LDL cholesterol and known atherosclerotic cardiovascular disease or HeFH. The trials were conducted in United States, Canada, and Europe.
=== Selected studies === NBRC researchers have used magnetic resonance spectroscopy to study brain chemistry in Alzheimer's disease. Studies reported depletion of the antioxidant glutathione in the hippocampus and in frontal and cingulate regions, which the researchers linked to cognitive decline, and a shift towards alkalinity in the pH of the left hippocampal formation. A multi-centre study identified open and closed conformations of glutathione in the brains of healthy young participants. The same technique was used in a 2021 study of brain chemistry in people who had recovered from COVID-19 or had been asymptomatic, which examined glutamate and GABA levels as possible markers of mental health. A 2020 study examined the role of the thalamus in the reorganisation of connectivity between large-scale brain networks during healthy ageing. In a collaborative study, researchers found that dengue and Japanese encephalitis viruses cause platelets to release platelet factor 4, which suppresses interferon production; blocking its receptor CXCR3 inhibited viral replication in laboratory and animal experiments. Another study found that the Zika virus envelope protein alters the properties of human fetal neural stem cells by modulating microRNA circuitry, a mechanism examined in relation to Zika-associated microcephaly. Work in roundworms showed that the microRNA let-7 regulates axonal self-fusion, a process that restored touch sensation after nerve injury.
=== Chalcogenides, pnictides, and carbides === Neptunium chalcogen and pnictogen compounds have been well studied primarily as part of research into their electronic and magnetic properties and their interactions in the natural environment. Pnictide and carbide compounds have also attracted interest because of their presence in the fuel of several advanced nuclear reactor designs, although the latter group has not had nearly as much research as the former.
Sources: en.wikipedia.org
Earthworms are classified into three main ecophysiological categories: (1) leaf litter- or compost-dwelling worms that are nonburrowing, live at the soil-litter interface and eat decomposing organic matter (epigeic) e.g. Eisenia fetida; (2) topsoil- or subsoil-dwelling worms that feed on soil, burrow and cast within the soil, creating horizontal burrows in upper 10–30 cm of soil (endogeic); and (3) worms that construct permanent deep vertical burrows which they use to visit the surface to obtain plant material for food, such as leaves (anecic, meaning "reaching up"), e.g. Lumbricus terrestris. Earthworm populations depend on both physical and chemical properties of the soil, such as temperature, moisture, pH, salts, aeration, and texture, as well as available food, competition, predation, and the ability of the species to reproduce and disperse. One of the most important environmental factors is pH, but earthworms vary in their pH preferences, and through their engineering activities (summarized in the formation of earthworm mull humus) they are able to change pH in order to adapt it to their niche requirements (see niche construction and extended phenotype). Most favour neutral to slightly acidic soils. However, Lumbricus terrestris is still present in a pH of 5.4, Dendrobaena octaedra at a pH of 4.3 and some Megascolecidae are present in extremely acidic humic soils. Soil pH may also influence the numbers of worms that go into diapause. The more acidic the soil, the sooner worms go into diapause, and remain in diapause the longest time at a pH of 6.4.
=== RFLP === A restriction fragment length polymorphism results in the cleavage (or absence thereof) of DNA for a specific mutation by a selected restriction enzyme that will not cleave the wildtype DNA. In a study using a mixture of wildtype and mutation containing DNA amplified by regular PCR or COLD-PCR, COLD-PCR preceding RFLP analysis was shown to improve the mutation detection by 10-20 fold.
==== World Health Organization ==== On January 22, 2026, President Donald Trump completed the withdrawal of the United States from the World Health Organization (WHO), a specialized agency of the United Nations, a year after he signed Executive Order 14155 on January 20, 2025. As announced by the Department of Health and Human Services, the United States officially exited the organization, ending its 78-year membership and halting all U.S. funding and participation in the WHO's governance and activities. Although the organization hoped for a reconsideration the day after Trump's executive order, the administration continued with the decision. The administration justified the withdrawal by citing concerns about the WHO's handling of global health emergencies, including the COVID-19 pandemic, its resistance to reforms, and its failure to operate independently from inappropriate political influence of other WHO member states. In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy Jr., they said that the WHO "tarnished and trashed everything that America has done for it" and it "abandoned its core mission and acted repeatedly against the interests of the United States", including the failure to "hand over the American flag that hung in front of it". The United States still owes outstanding dues to the WHO from 2024 to 2025, raising questions about the legality and financial implications of the exit.
Sources: en.wikipedia.org
The rearmament of West Germany was achieved in the early 1950s. Its main promoter was Konrad Adenauer, the chancellor of West Germany, with France the main opponent. Washington had the decisive voice. It was strongly supported by the Pentagon (the US military leadership), and weakly opposed by President Truman; the State Department was ambivalent. The outbreak of the Korean War in June 1950 changed the calculations and Washington now gave full support. That also involved naming Dwight D. Eisenhower in charge of NATO forces and sending more American troops to West Germany. There was a strong promise that West Germany would not develop nuclear weapons. Widespread fears of another rise of German militarism necessitated the new military to operate within an alliance framework under NATO command. In 1955, Washington secured full German membership of NATO. In May 1953, Lavrentiy Beria, by then in a government post, had made an unsuccessful proposal to allow the reunification of a neutral Germany to prevent West Germany's incorporation into NATO, but his attempts were cut short after he was executed several months later during a Soviet power struggle. The events led to the establishment of the Bundeswehr, the West German military, in 1955.
=== August === August 13, 2008: Estonia The Baltic state slides into recession with a 0.9% fall in second-quarter GDP after a drop of 0.5% in the first quarter. It falls deeper into recession in the third quarter when the economy contracted 3.3%.
== Prognosis == The availability of treatments that modify the course of multiple sclerosis beginning in the 1990s, known as disease-modifying therapies (DMTs), has improved prognosis. These treatments can reduce relapses and slow progression, but there is no cure. Before the advent of these medications, it took around 15 years before relapsing-remitting MS progressed to secondary progressive MS (which has associated mobility issues). With these medications, the progression is slower to 40 years. The prognosis of MS depends on the subtype of the disease, and there is considerable individual variation in the progression of the disease. In relapsing MS, the most common subtype, a 2016 cohort study found that after a median of 16.8 years from onset, one in ten needed a walking aid, and almost two in ten transitioned to secondary progressive MS, a form characterized by more progressive decline. With treatments available in the 2020s, relapses can be eliminated or substantially reduced. However, "silent progression" of the disease still occurs. In addition to secondary progressive MS (SPMS), a small proportion of people with MS (10–15%) experience progressive decline from the onset, known as primary progressive MS (PPMS). Most treatments have been approved for use in relapsing MS; there are fewer treatments with lower efficacy for progressive forms of MS. The prognosis for progressive MS is worse, with faster accumulation of disability, though with considerable individual variation.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.